- Home
- HQI vs NKTX Comparison
HQI vs NKTX Comparison
Compare HQI & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- NKTX
- Stock Information
- Founded
- HQI 2002
- NKTX 2015
- Country
- HQI United States
- NKTX United States
- Employees
- HQI N/A
- NKTX N/A
- Industry
- HQI Professional Services
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- NKTX Health Care
- Exchange
- HQI Nasdaq
- NKTX Nasdaq
- Market Cap
- HQI 143.3M
- NKTX 123.5M
- IPO Year
- HQI N/A
- NKTX 2020
- Fundamental
- Price
- HQI $9.94
- NKTX $2.07
- Analyst Decision
- HQI Strong Buy
- NKTX Strong Buy
- Analyst Count
- HQI 2
- NKTX 6
- Target Price
- HQI $16.00
- NKTX $14.40
- AVG Volume (30 Days)
- HQI 14.4K
- NKTX 583.8K
- Earning Date
- HQI 08-07-2025
- NKTX 08-12-2025
- Dividend Yield
- HQI 2.46%
- NKTX N/A
- EPS Growth
- HQI N/A
- NKTX N/A
- EPS
- HQI 0.24
- NKTX N/A
- Revenue
- HQI $33,651,000.00
- NKTX N/A
- Revenue This Year
- HQI N/A
- NKTX N/A
- Revenue Next Year
- HQI $4.99
- NKTX N/A
- P/E Ratio
- HQI $40.30
- NKTX N/A
- Revenue Growth
- HQI N/A
- NKTX N/A
- 52 Week Low
- HQI $9.04
- NKTX $1.31
- 52 Week High
- HQI $15.75
- NKTX $6.63
- Technical
- Relative Strength Index (RSI)
- HQI 47.31
- NKTX 54.51
- Support Level
- HQI $9.66
- NKTX $2.01
- Resistance Level
- HQI $10.13
- NKTX $2.32
- Average True Range (ATR)
- HQI 0.41
- NKTX 0.15
- MACD
- HQI -0.03
- NKTX 0.00
- Stochastic Oscillator
- HQI 32.71
- NKTX 52.83
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.